Advanced Research and Development of Chemical, Biological, Radiological, and Nuclear Medicine Countermeasures

BARDA encourages the advanced research, development and acquisition of medical countermeasures such as vaccines, therapeutics, and diagnostics, as well as innovative approaches to meet the threat of CBRN agents in support of the preparedness mission and priorities of the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) articulated in the PHEMCE Implementation Plan for CBRN Threats. The Implementation Plan is located on the ASPR website: http://www.phe.gov/about/amcg/ard/Pages/default.aspx.

In addition, the Pandemic and All Hazard Preparedness Act (PAHPA) directs BARDA to promote (i) innovations in technologies that may assist countermeasure and product advanced research and development (ii) research on and development of research tools and other devices and technologies and (iii) research to promote strategic initiations. The PAHPA is also located on the ASPR website: http://www.phe.gov/about/amcg/ard/Pages/default.aspx.

The purpose of this BAA is to solicit proposals that focus on one or more of the following areas of interest as listed here and further described in Part I.
Research Areas of Interest:

1. Vaccines Development
2. Antitoxins and Therapeutics
3. Antimicrobials and Antivirals
4. Radiological and Nuclear Agent Countermeasures
5. Chemical Agent Countermeasures
6. Diagnostics

BARDA anticipates that research and development activities awarded from this Broad Agency Announcement (BAA) will serve to advance the knowledge and scientific understanding of candidates' countermeasures for CBRN threats toward eventual FDA approval and their inclusion in the Strategic National Stockpile (SNS).

The Government intends to have a full & open competition for this requirement in the form of a BAA. The Government expects to make 1 or more awards, subject to the availability of funds.

Contact Information:

Comments to this announcement, referencing synopsis BARDA-CBRN-BAA-12-100-SOL-00011 may be submitted to CBRNBAA12.os@hhs.gov

Pre-proposal Conference:
The presentation slide show from Multi-BAA Pre-Proposal Conference (which was held on July 16, 2012 in Washington DC) is included as an attachment to this solicitation.

BARDA encourages the advanced research, development and acquisition of medical countermeasures such as vaccines, therapeutics, and diagnostics, as well as innovative approaches to meet the threat of CBRN agents in support of the preparedness mission and priorities of the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) articulated in the PHEMCE Implementation Plan for CBRN Threats. The Implementation Plan is located on the ASPR website: http://www.phe.gov/about/amcg/ard/Pages/default.aspx.

In addition, the Pandemic and All Hazard Preparedness Act (PAHPA) directs BARDA to promote (i) innovations in technologies that may assist countermeasure and product advanced research and development (ii) research on and development of research tools and other devices and technologies and (iii) research to promote strategic initiations. The PAHPA is also located on the ASPR website: http://www.phe.gov/about/amcg/ard/Pages/default.aspx.

The purpose of this BAA is to solicit proposals that focus on one or more of the following areas of interest as listed here and further described in Part I.
Research Areas of Interest:

1. Vaccines Development
2. Antitoxins and Therapeutics
3. Antimicrobials and Antivirals
4. Radiological and Nuclear Agent Countermeasures
5. Chemical Agent Countermeasures
6. Diagnostics

BARDA anticipates that research and development activities awarded from this Broad Agency Announcement (BAA) will serve to advance the knowledge and scientific understanding of candidates' countermeasures for CBRN threats toward eventual FDA approval and their inclusion in the Strategic National Stockpile (SNS).

The Government intends to have a full & open competition for this requirement in the form of a BAA. The Government expects to make 1 or more awards, subject to the availability of funds.

Contact Information:

Comments to this announcement, referencing synopsis BARDA-CBRN-BAA-12-100-SOL-00011 may be submitted to CBRNBAA12.os@hhs.gov

Pre-proposal Conference:

Please note that a Pre-Proposal Conference will take place in Washington, DC at the Humphrey Building (DHHS Headquarters) on Monday, July 16. Please look in the posted BAA for information regarding time, registration, the call in number, and other attendance requirements. It is recommended that you register as soon as possible, as the room has a capacity limit.

BARDA encourages the advanced research, development and acquisition of medical countermeasures such as vaccines, therapeutics, and diagnostics, as well as innovative approaches to meet the threat of CBRN agents in support of the preparedness mission and priorities of the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) articulated in the PHEMCE Implementation Plan for CBRN Threats. The Implementation Plan is located on the ASPR website: http://www.phe.gov/about/amcg/ard/Pages/default.aspx.

In addition, the Pandemic and All Hazard Preparedness Act (PAHPA) directs BARDA to promote (i) innovations in technologies that may assist countermeasure and product advanced research and development (ii) research on and development of research tools and other devices and technologies and (iii) research to promote strategic initiations. The PAHPA is also located on the ASPR website: http://www.phe.gov/about/amcg/ard/Pages/default.aspx.

The purpose of this BAA is to solicit proposals that focus on one or more of the following areas of interest as listed here and further described in Part I.
Research Areas of Interest:

1. Vaccines Development
2. Antitoxins and Therapeutics
3. Antimicrobials and Antivirals
4. Radiological and Nuclear Agent Countermeasures
5. Chemical Agent Countermeasures
6. Diagnostics

BARDA anticipates that research and development activities awarded from this Broad Agency Announcement (BAA) will serve to advance the knowledge and scientific understanding of candidates' countermeasures for CBRN threats toward eventual FDA approval and their inclusion in the Strategic National Stockpile (SNS).

The Government intends to have a full & open competition for this requirement in the form of a BAA. This synopsis is not a BAA; a BAA is anticipated on March 4, 2012. The Government expects to make 1 or more awards, subject to the availability of funds.

Contact Information:

Comments to this announcement, referencing synopsis BARDA-CBRN-BAA-12-100-SOL-00011 may be submitted to CBRNBAA12.os@hhs.gov

Pre-proposal Conference:

It is anticipated that a pre-proposal conference will be held in late April, 2012, at the following address:

200 Independence Avenue S.W.
Hubert H Humphrey Building 7th floor Room 725A
Washington, DC 20201

Instructions regarding access to the meeting and dial-in information will be posted prior to the meeting.

BARDA encourages the advanced research, development and acquisition of medical countermeasures such as vaccines, therapeutics, and diagnostics, as well as innovative approaches to meet the threat of CBRN agents in support of the preparedness mission and priorities of the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) articulated in the PHEMCE Implementation Plan for CBRN Threats. The Implementation Plan is located on the ASPR website: http://www.phe.gov/about/amcg/ard/Pages/default.aspx.

In addition, the Pandemic and All Hazard Preparedness Act (PAHPA) directs BARDA to promote (i) innovations in technologies that may assist countermeasure and product advanced research and development (ii) research on and development of research tools and other devices and technologies and (iii) research to promote strategic initiations. The PAHPA is also located on the ASPR website: http://www.phe.gov/about/amcg/ard/Pages/default.aspx.

The purpose of this BAA is to solicit proposals that focus on one or more of the following areas of interest as listed here and further described in Part I.
Research Areas of Interest:

1. Vaccines Development
2. Antitoxins and Therapeutics
3. Antimicrobials and Antivirals
4. Radiological and Nuclear Agent Countermeasures
5. Chemical Agent Countermeasures
6. Diagnostics

BARDA anticipates that research and development activities awarded from this Broad Agency Announcement (BAA) will serve to advance the knowledge and scientific understanding of candidates' countermeasures for CBRN threats toward eventual FDA approval and their inclusion in the Strategic National Stockpile (SNS).

The Government intends to have a full & open competition for this requirement in the form of a BAA. This synopsis is not a BAA; a BAA is anticipated on March 4, 2012. The Government expects to make 1 or more awards, subject to the availability of funds.

Contact Information:

Comments to this announcement, referencing synopsis BARDA-CBRN-BAA-12-100-SOL-00011 may be submitted to CBRN-BAA-12@hhs.gov

Pre-proposal Conference:

It is anticipated that a pre-proposal conference will be held in late April, 2012, at the following address:

200 Independence Avenue S.W.
Hubert H Humphrey Building 7th floor Room 725A
Washington, DC 20201

Instructions regarding access to the meeting and dial-in information will be posted prior to the meeting.